Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Texas Instruments Incorporated (TXN) vs Zoetis Inc (ZTS) Price & Performance

Texas Instruments IncorporatedTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Texas Instruments Incorporated vs Zoetis Inc — how do they compare? Texas Instruments Incorporated trades at $282.93 (market cap $263.20B), while Zoetis Inc trades at $74.33 (market cap $30.20B). The key difference: Texas Instruments Incorporated is far larger — about 8.7× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Texas Instruments Incorporated for 76 Days and Zoetis Inc for 70 Days on average.

TXNZTS
Market Cap
$263.20B$30.20B
Volume
5,850,2566,175,327
Sector
TechnologyHealth
52-Week High
$332.35$147.53
52-Week Low
$153.33$69.09
Typical Hold Time
76 Days70 Days
Enterprise Value
$270.25B$37.76B
Dividend Yield
2.11%2.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Texas Instruments Incorporated

Texas Instruments (TXN) trades at $288.94, down 2.82% on the day, amid a broader semiconductor sell-off. The stock maintains a bullish technical outlook with strong moving average signals and key support at $286. Fundamentally, revenue and earnings are recovering, with Q2 2026 EPS beating expectations at $2.14 versus $1.91, driven by data center sales growth and margin expansion. The company's net income margin stands at 31.11%, with robust cash flow from operations of $7.15 billion in 2025.

The outlook for TXN is positive, supported by accelerating data center demand, AI infrastructure investments, and a consensus price target of $325 implying 12% upside. Risks include premium valuation with a P/E of 43.8 and rising debt-to-asset ratio of 40.61% in 2025. Analyst sentiment is bullish with 47.69% buy ratings, though competitive pressures and cyclical semiconductor demand pose headwinds.

Zoetis Inc

Zoetis (ZTS) trades at $71.55, showing modest daily gains of 0.32% amid a challenging market environment. The stock faces bearish technical signals with mixed earnings performance, having beaten estimates in Q2 2026 but missing in Q1. Despite recent headwinds in U.S. companion animal sales, the company maintains strong profitability with 71.67% gross margins and 27.69% net income margins. Analyst consensus remains positive with a $87.33 price target, though technical indicators suggest near-term pressure with support at $70-$71.

Zoetis presents a compelling value opportunity with attractive valuation multiples (P/E 11.92, EV/EBITDA 9.4) and robust fundamentals, though near-term risks include competitive pressures in pet medications and weakening U.S. veterinary clinic traffic. The company's international and livestock segments show resilience, supporting long-term growth potential despite current market skepticism.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

TXN
39% Buy61% Sell
Avg holding period · 76 Days
ZTS

No sentiment data available yet.

Top news

Latest headlines on both assets

About Texas Instruments Incorporated

Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.

Read more on TXN →

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS →